In the US, the government is increasingly prioritizing biosecurity and biodefense. Last quarter, we announced a new contract with the CDC to expand our traveler-based COVID-19 genomic surveillance program at certain US airports.

Nov 14, 2022 / CEO / receipt, needs a key / Jason Kelly, CEO | earnings call 2022-11-14 | transcript 8c4241d1-cf1c-4a6e-9c19-cc8a22614c29 | chars 36954-37182 | segment 37

While our K-12 testing business has been quieter over the summer, just because many schools are closed, as expected, we're very excited to be seeing traction across longer-term biosecurity opportunities, including being awarded a contract from the CDC to expand our traveler-based COVID-19 monitoring services, with an overall potential to exceed $61 million to Ginkgo and its partners based on CDC program options and public health priorities.

Aug 15, 2022 / CEO / receipt, needs a key / Jason Kelly, CEO | earnings call 2022-08-15 | transcript cd3afc1c-982a-4f10-9827-ea3fabebb282 | chars 5018-5462 | segment 5